Basic information and marketing trends of kovalizumab

Crovalimab (Crovalimab), as a new complement C5 inhibitor, is 13 It brings new treatment hope to patients with paroxysmal nocturnal hemoglobinuria (PNH) who are 40kg and weigh at least 40kg. PNHIt is a rare and serious blood disease. Patients suffer from anemia, thrombosis, pancytopenia and dark urine due to excessive hemolysis of red blood cells. The indications of corvalizumab are clear, especially for those patients who show symptoms of hemolysis and high disease activity, as well as those who have been stably treated with other C5 inhibitors for at least 6 months. It provides a new treatment idea.

It is worth mentioning that kovalizumab will usher in its important launch moment in2024. On 2 on February 6, China’s National Medical Products Administration approved the marketing application for kovarizumab injection, with the trade name Pasika, marking its first approval globally. Subsequently, in June of the same year, the United States also approved the listing of kovarizumab under the trade name Piasky, further broadening its international market coverage.

However, since kovalizumab has not been on the market for a long time, it has not yet been included in my country's medical insurance system, and its price has not yet been determined. For patients, in addition to considering the efficacy and safety of the drug, price is also an important consideration when choosing treatment. And drug prices are affected by many factors, including sales channels, regional differences and medical insurance policies, so the actual prices may fluctuate. Patients who are in need of corvalizumab can pay attention to drug information and marketing trends in a timely manner.

The use of kovalizumab may also be associated with some side effects, including infusion-related reactions, viral infections, respiratory infections (such as lung infections), and Type III allergic reactions, such as pain or swelling of the nose or throat. Patients should pay close attention to these reactions during treatment and communicate with their doctors in a timely manner.

Reference link:https://www.accessdata.fda.gov/drugsatfda docs/label/2024/761388s000lbl.pdf